348 reports of this reaction
1.4% of all RIZATRIPTAN BENZOATE reports
#18 most reported adverse reaction
NEPHROLITHIASIS is the #18 most commonly reported adverse reaction for RIZATRIPTAN BENZOATE, manufactured by Organon LLC. There are 348 FDA adverse event reports linking RIZATRIPTAN BENZOATE to NEPHROLITHIASIS. This represents approximately 1.4% of all 24,816 adverse event reports for this drug.
Patients taking RIZATRIPTAN BENZOATE who experience nephrolithiasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEPHROLITHIASIS is a less commonly reported adverse event for RIZATRIPTAN BENZOATE, but still significant enough to appear in the safety profile.
In addition to nephrolithiasis, the following adverse reactions have been reported for RIZATRIPTAN BENZOATE:
The following drugs have also been linked to nephrolithiasis in FDA adverse event reports:
NEPHROLITHIASIS has been reported as an adverse event in 348 FDA reports for RIZATRIPTAN BENZOATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEPHROLITHIASIS accounts for approximately 1.4% of all adverse event reports for RIZATRIPTAN BENZOATE, making it a notable side effect.
If you experience nephrolithiasis while taking RIZATRIPTAN BENZOATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.